Research Overview

Our research aims to expand the bounds of druggability for both fundamental and therapeutic discoveries. We achieve this through the development of covalent chemical tools and the leveraging of chemical proteomic technologies. We are particularly interested in developing chemical tools targeting proteins that drive cancers and immune disorders with unmet clinical needs. We pursue this goal through integration with genetic and phenotypic approaches across three interconnected areas: (1) Exploration of new covalent chemical space: Developing new chemical scaffolds to uncover new molecular targets; (2) Chemoproteomics-enanbled parallel ligand and target discovery: From mapping allosteric pockets in oncogenic proteins to developing chemical modulators of protein–protein interactions; and (3) Fundamental biology and therapeutic discoveries: From defining roles for unannotated proteins to validating new molecular vulnerabilities. Through this integrated strategy, we hope to find chemical starting points to expand our understanding of fundamental biology and to develop next-generation therapeutics.